Make it better together

06th November 2026

To
The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **SAILIFE**

To
The Corporate Relations Department,
BSE Limited
BSE Scrip code: **544306**

Dear Sir/Madam,

Ref: **Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").**

Sub: **Press release on the Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended 30th September 2026.**

Pursuant to Regulation 30 of SEBI Listing Regulations we are enclosing herewith the "Press Release on Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended 30th September 2026" being issued by the Company.

Further, the above-mentioned press release is also available on the Website of the Company on following path: https://sailife.com/#**> Investors> Financial Information> FY 2027> Earnings Release> Q2> Download (**https://sailife.com/financial-information/**)**.

Kindly take the above information on your record.

Thanking you.

Yours sincerely,
For **Sai Life Sciences Limited**

RUNA KARAN
Digitally signed by RUNA KARAN
Date: 2026.11.06 00:07:00 +05'30'

Runa Karan
Company Secretary & Compliance Officer
Membership No. A13721

Encl.: As Above

Sai Life Sciences delivers strong growth with healthy operating performance

Reported Q2 FY27 revenue growth of 23% YoY, sustaining EBITDA margin

Hyderabad, November 05, 2026: Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), one of India's fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO) announced its financial results for the second quarter and half year ended September 2026.

Commenting on the performance during the quarter, Mr. Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences Limited, said, *"Q2 FY27 was a strong quarter for Sai, with continued business momentum and progress across our key strategic priorities. We see growing traction with global pharmaceutical companies, increasing adoption of our integrated outsourcing model, and continued progress in building the capacity and capabilities required to support customers over the long term. Importantly, we are seeing customer engagements evolve from individual projects into larger, more strategic relationships spanning discovery, development and manufacturing."*

Mr. Siva Chittor, Chief Financial Officer, Sai Life Sciences Limited added, *"We are pleased to report a healthy performance this quarter, with revenue growing by 23% year-on-year. The performance was broad-based, with both CRO and CDMO delivering healthy growth, while EBITDA margins stood at 28%. We continue to expect a stronger second half, supported by the progression of our development and commercial pipeline and the ramp-up of new capacity. Our capacity and capability expansion programme remains on track with a total of ₹621 crore invested in H1 FY27."*

Financial Performance:

Particulars (₹ crores)	Q2FY27	Q2FY26	YoY%	H1FY27	H1FY26	YoY%
Revenue from Operations	**659**	**537**	**23%**	**1,213**	**1,034**	**17%**
EBITDA	**187**	**156**	**20%**	**335**	**281**	**19%**
EBITDA Margin%	*28%*	*29%*		*28%*	*27%*	
PAT	**98**	**84**	**17%**	**172**	**144**	**19%**
PAT Margin%	*15%*	*16%*		*14%*	*14%*	

Key Highlights

- Revenue from Operations was ₹1,213 Cr for H1FY27 compared to ₹1,034 Cr in H1FY26, an increase of 17%
- EBITDA stood at ₹335 Cr for H1FY27 compared to ₹281 Cr in H1FY26, an increase of 19%
- PAT stood at ₹172 Cr for H1FY27 compared to ₹144 Cr in H1FY26, an increase of 19%
- Incurred Capex of ₹621 Cr in H1FY27

Earnings Call:

Sai Life Sciences will conduct earnings call at 11.00 AM (IST) on 06 November 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date	**November 06, 2026**
Time	11:00 AM – 12:00 PM (IST)
Dial-in Number	**+91 22 6280 1107, +91 22 7115 8008**
International Toll Free	USA: 18667462133 | UK: 08081011573 | Singapore: 8001012045 | Hong Kong: 800964448
Pre-Registration Facility	**Click here**

About Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE)

Sai Life Sciences is one of India's fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Headquartered in Hyderabad, India, with a strong global presence, the company offers integrated solutions spanning discovery, process development, clinical and commercial manufacturing, and advanced technology platforms. Sai Life Sciences is committed to delivering high-quality, cost-effective, and scalable solutions while upholding the highest standards of safety, compliance, and integrity. With a focus on innovation and operational excellence, the company continues to strengthen its capabilities to support emerging therapeutic modalities and meet the evolving needs of the life sciences industry.

For more information, please visit www.sailife.com

For further details, please feel free to contact: Investorrelation@sailife.com

Disclaimer:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Sai Life, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.